pI: 8.6379 |
Length (AA): 460 |
MW (Da): 51688 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
1 | 42 | 1ps9 (A) | 345 | 386 | 29.00 | 0.11 | 0.01 | 0.105104 | 2.59 |
28 | 458 | 1lqt (A) | 2 | 451 | 30.00 | 0 | 1 | 1.27476 | -0.37 |
29 | 458 | 1cjc (A) | 6 | 455 | 40.00 | 0 | 1 | 1.41608 | -0.67 |
32 | 458 | 1lqt (A) | 6 | 451 | 32.00 | 0 | 1 | 1.28256 | -0.3 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_128406)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT4G32360 | pyridine nucleotide-disulfide oxidoreductase family protein |
Babesia bovis | BBOV_I000680 | conserved hypothetical protein |
Brugia malayi | Bm1_54850 | NADPH:adrenodoxin oxidoreductase, mitochondrial precursor |
Candida albicans | CaO19.3521 | highly similar to N terminus of S. cerevisiae ARH1 (YDR376W) mitochondrial adrenodoxin-like oxidoreductase |
Candida albicans | CaO19.8040 | similar to adrenodoxin oxidoreductase, ferredoxin-NADP+ reductase, EC 1.18.1.2, mitochondrial in S. cerevisiae |
Candida albicans | CaO19.11004 | highly similar to N terminus of S. cerevisiae ARH1 (YDR376W) mitochondrial adrenodoxin-like oxidoreductase |
Candida albicans | CaO19.410 | similar to adrenodoxin oxidoreductase, ferredoxin-NADP+ reductase, EC 1.18.1.2, mitochondrial in S. cerevisiae |
Caenorhabditis elegans | CELE_Y62E10A.6 | Protein Y62E10A.6 |
Cryptosporidium hominis | Chro.80316 | NADPH:ferredoxin oxidoreductase |
Cryptosporidium parvum | cgd8_2710 | NADPH:ferredoxin--NADP+ reductase with a rossman fold nucleotide binding domain and a 2Fe-2S ferredoxin domain |
Dictyostelium discoideum | DDB_G0287353 | NADPH:ferredoxin oxidoreductase |
Drosophila melanogaster | Dmel_CG12390 | defective in the avoidance of repellents |
Echinococcus granulosus | EgrG_000599900 | NADPH:adrenodoxin oxidoreductase |
Echinococcus multilocularis | EmuJ_000599900 | NADPH:adrenodoxin oxidoreductase |
Homo sapiens | ENSG00000161513 | ferredoxin reductase |
Leishmania braziliensis | LbrM.21.0480 | ferredoxin NADP reductase-like protein |
Leishmania donovani | LdBPK_210480.1 | NADPH:adrenodoxin oxidoreductase, mitochondrial, putative |
Leishmania infantum | LinJ.21.0480 | ferredoxin NADP reductase-like protein |
Leishmania major | LmjF.21.0420 | ferredoxin NADP reductase-like protein |
Leishmania mexicana | LmxM.21.0420 | ferredoxin NADP reductase-like protein |
Loa Loa (eye worm) | LOAG_13401 | hypothetical protein |
Loa Loa (eye worm) | LOAG_04928 | hypothetical protein |
Mycobacterium leprae | ML0666c | Probable NADPH:adrenodoxin oxidoreductase FprA (NADPH-FERREDOXIN REDUCTASE) |
Mus musculus | ENSMUSG00000018861 | ferredoxin reductase |
Mycobacterium tuberculosis | Rv3106 | NADPH:adrenodoxin oxidoreductase FprA (NADPH-ferredoxin reductase) |
Mycobacterium ulcerans | MUL_2413 | NADPH:adrenodoxin oxidoreductase FprA |
Mycobacterium ulcerans | MUL_2699 | NADPH:adrenodoxin oxidoreductase FprA |
Neospora caninum | NCLIV_026250 | NADPH:adrenodoxin oxidoreductase FprB, related |
Oryza sativa | 4329009 | Os02g0277600 |
Onchocerca volvulus | OVOC207 | NADPH:adrenodoxin oxidoreductase, mitochondrial homolog |
Plasmodium berghei | PBANKA_0909300 | adrenodoxin reductase, putative |
Plasmodium falciparum | PF3D7_1139700 | adrenodoxin reductase, putative |
Plasmodium knowlesi | PKNH_0937600 | adrenodoxin reductase, putative |
Plasmodium vivax | PVX_192290 | unspecified product |
Plasmodium vivax | PVX_202290 | unspecified product |
Plasmodium vivax | PVX_092585 | adrenodoxin reductase, putative |
Plasmodium vivax | PVX_191290 | unspecified product |
Plasmodium yoelii | PY02070 | MFDR, putative |
Saccharomyces cerevisiae | YDR376W | Arh1p |
Schistosoma japonicum | Sjp_0217420 | ko:K00528 ferredoxin--NADP+ reductase [EC1.18.1.2], putative |
Schistosoma mansoni | Smp_166580 | ferredoxin/ferredoxin--NADP reductase-related |
Schmidtea mediterranea | mk4.001786.00 | NADPH:adrenodoxin oxidoreductase, mitochondrial |
Trypanosoma brucei gambiense | Tbg972.10.2700 | adrenodoxin reductase, putative,ferredoxin NADP reductase-like protein |
Trypanosoma brucei | Tb927.10.2230 | NADPH:adrenodoxin oxidoreductase, mitochondrial, putative |
Trypanosoma congolense | TcIL3000_10_1840 | NADPH:adrenodoxin oxidoreductase, mitochondrial, putative |
Trypanosoma cruzi | TcCLB.511367.230 | NADPH:adrenodoxin oxidoreductase, mitochondrial, putative |
Toxoplasma gondii | TGME49_261030 | pyridine nucleotide-disulfide oxidoreductase domain-containing protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu3159 | Mycobacterium tuberculosis | non-essential | nmpdr |
Tb927.10.2230 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.2230 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.2230 | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb927.10.2230 | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_Y62E10A.6 | Caenorhabditis elegans | embryonic arrest | wormbase |
YDR376W | Saccharomyces cerevisiae | inviable | yeastgenome |
PBANKA_0909300 | Plasmodium berghei | Essential | plasmo |
TGME49_261030 | Toxoplasma gondii | Probably essential | sidik |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.